Tokyo’s Chugai Pharmaceutical (TYO: 4519) has secured a label update for Kadcyla (trastuzumab) from the Japanese Ministry of Health, Labor and Welfare.
Chugai will now be able to market the therapy, the first HER2-targeting antibody-drug conjugate, for people with HER2-positive postoperative breast cancer.
This approval is based on the results from an open-label, randomized, global Phase III KATHERINE study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze